Cargando…
Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
The introduction in clinical practice of pharmaceutical products known as biosimilars, as part of a more complex series of progress in the field of biological drugs, represents an excellent therapeutic resource. A biosimilar drug is a biological/biotechnological drug that is highly similar to an app...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Healthcare
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5315076/ https://www.ncbi.nlm.nih.gov/pubmed/28261647 http://dx.doi.org/10.1007/s40487-016-0028-9 |